PANDION THERAPEUTICS, INC. Capital Expenditures
PANDION THERAPEUTICS, INC. reported Capital Expenditures of $2.79 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2021-03-12
- PANDION THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2020-12-31 was $783.00K, a 295.45% increase year-over-year.
- PANDION THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2020-09-30 was $777.00K.
- PANDION THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2019-12-31 was $198.00K.
- PANDION THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2019-09-30 was $0.00.
- PANDION THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2020 was $2.79M, a 339.06% increase from fiscal 2019.
- PANDION THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2019 was $635.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2020-12-31 | $783.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $1.56M derived: sum of 2 quarters · filed 2021-03-12 | $2.79M 10-K · filed 2021-03-12 | |
| 2020-09-30 | $777.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $2.00M 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $1.23M 10-Q · filed 2020-08-31 | |||
| 2019-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $198.00K derived: sum of 2 quarters · filed 2021-03-12 | $635.00K 10-K · filed 2021-03-12 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $437.00K 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $437.00K 10-Q · filed 2020-08-31 |